Skip to content
value.today

Asher Biotherapeutics, Inc.

Total raised
$163 M
2 rounds on record
Latest round
$55 M
Apr 2024
First round on record
Aug 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Asher Biotherapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2024$55 MNo. 2$50 to $250 million

Asher Biotherapeutics, Inc.: Raise no. 2, Apr 2024

Investors in this round

16 investors had bought by the notice of Apr 16, 2024: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Asher Biotherapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$55 M of $55 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andy Yeung · Executive Officer
  • Craig Gibbs · Executive Officer, Director
  • Don O'Sullivan · Executive Officer
  • Ivana Djuretic · Executive Officer, Director
  • Kyle Elrod · Executive Officer
  • Bob Deresiewicz · Director
  • Elaine Sun · Director
  • Ian Clark · Director
  • Jeffrey Tong · Director
  • Reid Huber · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Craig Gibbs, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 16, 2024. Read the notice at the SEC.

equitySEC
Aug 2021$108 MNo. 1$50 to $250 million

Asher Biotherapeutics, Inc.: Raise no. 1, Aug 2021

Investors in this round

22 investors had bought by the notice of Sep 7, 2021: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Asher Biotherapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$108 M of $108 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Craig Gibbs · Executive Officer, Director
  • Ivana Djuretic · Executive Officer, Director
  • Kyle Elrod · Executive Officer
  • Yik Andy Yeung · Executive Officer
  • Jeffrey Tong · Director
  • Reid Huber · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Craig Gibbs, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 7, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Asher Biotherapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2024).

    SEC Form D · Apr 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2024

That is all the official record says: Asher Biotherapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Asher Biotherapeutics, Inc.
InvestorKindAmountRoundRoleSource
Janus Henderson Global Life Sciences FundFund or asset manager$1 Mheldnot statedHolds shares (fund report, Jun 2026)SEC Form N-PORT

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Asher Biotherapeutics, Inc.
NameRoleNamed in
Andy YeungExecutive officerApr 2024
Craig GibbsExecutive officerApr 2024
Don O'SullivanExecutive officerApr 2024
Ivana DjureticExecutive officerApr 2024
Kyle ElrodExecutive officerApr 2024
Yik Andy YeungExecutive officerSep 2021
Bob DeresiewiczDirectorApr 2024
Craig GibbsDirectorApr 2024
Elaine SunDirectorApr 2024
Ian ClarkDirectorApr 2024
Ivana DjureticDirectorApr 2024
Jeffrey TongDirectorApr 2024
Reid HuberDirectorApr 2024